Recombinant human complement factor H - Eleva
Alternative Names: Compleva FH; CPV-104Latest Information Update: 09 Jul 2024
At a glance
- Originator Eleva
- Class Recombinant proteins
- Mechanism of Action Complement factor H replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Membranoproliferative glomerulonephritis
Most Recent Events
- 03 Jul 2024 Recombinant human complement factor H - Eleva receives Orphan Drug status for Membranoproliferative glomerulonephritis in European Union
- 30 May 2024 Recombinant human complement factor H is available for licensing as of 30 May 2024. https://elevabiologics.com/assets/ (Eleva pipeline, May 2024)
- 13 May 2024 Eleva plans a clinical trial in Membranoproliferative glomerulonephritis in H1 2025 (Parenteral)